


# VISCHER ACTED AS SWISS COUNSEL TO RELIEF THERAPEUTICS

*Posted on 1 February 2021*



Category: [Pharma](#)

Tags: [Christian Wyss](#), [Ex-Featured](#), [Florian Kambor](#), [Peter Kühn](#), [Robert Bernet](#), [Vischer](#)



**Relief Therapeutics Holding**, a biopharmaceutical company with the lead compound RLF-100TM (Aviptadil) in advanced clinical development for the treatment of severe Covid-19 cases, has a binding term sheet completed on the acquisition of all shares in AdVita, a Germany-based pharmaceutical company that develops effective products and strategies to improve the treatment and diagnosis of rare lung diseases, against payment of Relief shares worth EUR 25 millio. and possible future milestone payments of up to EUR 20 million. The completion of the transaction is subject to customary closing conditions and (securities regulatory) approvals and is expected in the second quarter of 2021.

## The advisors

**VISCHER [advises Relief as lead counsel and on the Swiss legal aspects of this transaction](#)**, while K&L Gates is acting as German counsel and Sterne Kessler is acting as US IP counsel. The VISCHER team, led by partner Robert Bernet (Corporate / M&A - pictured) includes Peter Kühn (Counsel, Corporate / M & A), Florian Kambor (Junior Associate, Corporate / M & A) and Christian Wyss (Partner, IP).

**[As previously reported by \*legalcommunity.ch\*, Kellerhals Carrard \[acted as legal advisor\]\(#\)](#)**

**to the founders of AdVita in this transaction.** The team was led by partner Emanuel Dettwiler (Corporate/M&A) and comprised senior associate Sophie Holdt (Corporate/M&A).